Gefitinib

Generic Name: Gefitinib

Brand Names: Iressa, Gefitinib Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄ClFN_₄O_₃

CAS Number: 184475-35-2

Unique Ingredient Identifier: S65743JHBS

Background: Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication: For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions: Metastatic Non-Small Cell Lung Cancer

Associated Therapies: -

Clinical Trials

Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy

Phase 1

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Gefitinib
Device: Radiation Therapy

First Posted Date: 2007-07-06

Last Posted Date: 2008-10-21

Lead Sponsor: Fudan University

Target Recruit Count: 32

Registration Number: NCT00497250

Locations: 🇨🇳
Fudan University, Cancer Hospital, Department of Radiation Oncology, Shanghai, China

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

Phase 2

Terminated

Conditions: Esophageal Cancer

Interventions: Drug: cisplatin
Drug: gefitinib
Drug: paclitaxel
Procedure: adjuvant therapy
Radiation: radiation therapy

First Posted Date: 2007-06-27

Last Posted Date: 2018-12-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 19

Registration Number: NCT00493025

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Iressa as Second Line Therapy in Advanced NSCLC-Asia

Phase 3

Completed

Conditions: NSCLC

Interventions: Drug: Gefitinib
Drug: Docetaxel

First Posted Date: 2007-05-24

Last Posted Date: 2012-06-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 163

Registration Number: NCT00478049

Locations: 🇰🇷
Research Site, Suwon, Korea, Republic of

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 2

Terminated

Conditions: Kidney Cancer

Interventions: Biological: PEG-interferon alfa-2b
Drug: gefitinib

First Posted Date: 2007-04-27

Last Posted Date: 2017-03-17

Lead Sponsor: California Cancer Consortium

Target Recruit Count: 21

Registration Number: NCT00467077

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Procedure: chemotherapy
Drug: Gefitinib

First Posted Date: 2007-04-04

Last Posted Date: 2010-10-25

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 315

Registration Number: NCT00455936

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
National Cancer Center, Korea, Goyang-si, Gyenggi-do, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

Phase 1

Conditions: Non-melanomatous Skin Cancer

First Posted Date: 2007-01-18

Last Posted Date: 2013-12-19

Lead Sponsor: University of California, San Diego

Target Recruit Count: 16

Registration Number: NCT00423397

Locations: 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2006-12-13

Last Posted Date: 2013-05-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 34

Registration Number: NCT00411047

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: Gefitinib

First Posted Date: 2006-12-08

Last Posted Date: 2010-09-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT00409006

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Gefitinib

First Posted Date: 2006-09-07

Last Posted Date: 2018-01-31

Lead Sponsor: David M. Jackman, MD

Target Recruit Count: 7

Registration Number: NCT00372515

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Iressa Follow-up Trial

Phase 3

Completed

Conditions: Breast Cancer
Lung Cancer

Interventions: Drug: Gefitinib

First Posted Date: 2006-07-27

Last Posted Date: 2016-08-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT00357734

Locations: 🇩🇪
Research Site, Tübingen, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy